Evidence map›Paper›PMID 41645138›Full record

ArticleBMC neurology2026

Analysis of risk factors for early neurological deterioration after intravenous thrombolysis in acute ischemic stroke.

Jiayu Tang, Gang Peng, Yiyi Luo, Jiahua Liang, Xiao Wang, Yan Wen, Chongyu Hu

Abstract read
In one paragraph

Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiayu Tang *The School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Gang Peng *The School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Yiyi Luo *The School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Jiahua Liang *The School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Xiao WangThe School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Yan WenThe School of Clinical Medicine, Hunan University of Chinese Medicine, No. 300, Bachelor Road, Hanpu Science and Education Park, Yuelu District, Changsha, Hunan Province, 410208, China.
Chongyu HuThe Second People's Hospital of Hunan Province (Brain Hospital of Hunan Province), 427 Furong Middle Road, Changsha, 410007, China. huchongyu2025@163.com.

Funding

Changsha Natural Science Foundation kq2403147Key Projects of Xiangjiang Laboratory 23XJ02006
6 · The paper itself

Abstract

backgroundEarly Neurological Deterioration (END) after intravenous thrombolysis (IVT) in Acute Ischemic Stroke (AIS) increases disability, death, and healthcare burden. Its mechanisms, possibly involving reperfusion injury and hemorrhagic transformation, are not fully understood, and current risk factors lack detailed pathophysiological explanations. Identifying reliable predictors for END is essential for early intervention.

methodsIn a single-center retrospective cohort study, a retrospective cohort study was conducted on 198 AIS patients who received IVT with recombinant tissue plasminogen activator (rt-PA) at Hunan Provincial Brain Hospital between October 2022 and December 2024. END was defined as an increase of ≥ 4 points in the National Institutes of Health Stroke Scale (NIHSS) score or death within 24 h after thrombolysis. We collected and compared demographic, clinical, laboratory (including inflammatory/thrombotic ratios: neutrophil-to-lymphocyte ratio (NLR), fibrinogen-to-albumin ratio (FAR), lactate dehydrogenase-to-albumin ratio (LAR), D-dimer-to-fibrinogen ratio (DFR)), and imaging data between the END and non-END groups. Univariate analyses, multivariate logistic regression, and ROC curve analysis were performed to identify independent risk factors and assess their predictive power. Of note, neurological status after 24 h was not routinely assessed with NIHSS in our stroke-unit protocol; Therefore we cannot report the incidence of deterioration beyond 24 h. This may have overestimated END frequency compared with studies using 48- or 72-h definitions.

resultsEND occurred in 50 patients (25.2%). Multivariate logistic regression identified five independent risk factors for END: history of atrial fibrillation (AF) (OR = 2.558, P = 0.003), higher pre-thrombolysis NIHSS score (OR = 1.118, P = 0.001), elevated lactate dehydrogenase (LDH) (OR = 1.087, P = 0.035), higher Fibrinogen-to-Albumin Ratio (FAR) (OR = 1.031, P = 0.008), and higher Lactate Dehydrogenase-to-Albumin Ratio (LAR) (OR = 2.129, P = 0.012). ROC analysis showed that LAR had the highest individual predictive value (AUC = 0.801, Sensitivity = 76.1%, Specificity = 76.3%). Combining NIHSS, LDH, FAR, and LAR provided the best prediction (AUC = 0.922, Sensitivity = 94.0%, Specificity = 74.3%). Of note, this high AUC reflects exploratory performance within a single retrospective cohort; the composite model is not intended for immediate clinical use and must be prospectively validated.

conclusionsOur study identifies LAR and FAR as new and important predictors of END after IVT, based on the pathophysiology involving hypoxic injury and the interplay of inflammation and coagulation, LAR and FAR are new and important predictors of END after IVT, which may aid in the early identification of high-risk patients for intensified monitoring.

Indexed as

Fibrinolytic AgentsIschemic StrokeNervous System DiseasesThrombolytic TherapyTissue Plasminogen ActivatorAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsFibrinolytic AgentsTissue Plasminogen ActivatorAcute ischemic strokeEarly neurological deteriorationIntravenous thrombolysisRisk factors

Identifiers

PMID41645138
PMCPMC12983711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.